Drug intelligence / Profile preview

RSV F subunit vaccine + MF59

Development stage
Unknown
Lead developer
GSK
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular, Intranasal
01

Overview

Protein subunit vaccine composed of the **respiratory syncytial virus (RSV) fusion (F) protein in its pre-fusion (preF) conformation** combined with the **MF59 oil-in-water emulsion adjuvant**. This combination is developed to enhance both systemic and mucosal immunity against RSV. The MF59 adjuvant increases the immunogenicity of the otherwise weakly immunogenic RSV F subunit by promoting robust systemic neutralizing antibody production (mainly IgG) and, when administered intranasally, boosting mucosal IgA responses and tissue-resident memory T cells. Intramuscular administration mainly induces systemic immunity, while combined or intranasal administration induces both systemic and mucosal immune responses. MF59 is a squalene-based adjuvant widely used to amplify immune responses for protein subunit vaccines[1][2].

Other names
RSV-F subunit vaccine + MF59MF59-adjuvanted preF protein vaccineMF-59-adjuvanted preF protein vaccineMF 59-adjuvanted preF protein vaccineMF59/preF
02

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on RSV F subunit vaccine + MF59.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSV F subunit vaccine + MF59.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call